Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. EGFR TKIs induce dramatic objective responses and increase survival in patients bearing sensitizing mutations in the EGFR intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Noto, Alessia, De Vitis, Claudia, Roscilli, Giuseppe, Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Luberto, Laura, D'Andrilli, Antonio, Coluccia, Pierpaolo, Giovagnoli, Maria Rosaria, Normanno, Nicola, Ruco, Luigi, Aurisicchio, Luigi, Mancini, Rita, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://www.ncbi.nlm.nih.gov/pubmed/23896512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://www.ncbi.nlm.nih.gov/pubmed/23896512

Ejemplares similares